Pharma Logistics Editorial

  1. FDA Publishes Final Guidance On Reporting Listed Drug Amounts 4/10/2024

    Despite earlier efforts to shore up the U.S. drug supply chain, COVID-19 still brought shortages. A new FDA reporting system aims to reduce future supply risks.

  2. Managing Supply Chain Risks Using Relational Risk Analysis 4/5/2024

    In the bio/pharma and medical device industries, you can easily model, understand, and manage supply chain risks using relational risk analysis. Here's how.

  3. What Really Happens When A Cell Therapy Supply Chain Fails? 4/5/2024

    A freezer left unpowered can have devastating effects on delicate supply chains. These true stories led to tough lessons for biotech companies producing personalized medicine.

  4. A Guide To Proactive Supplier Management In The Pharma/Biotech Industry 3/21/2024

    Proactively mitigate supply disruptions with strategic supplier selection and diversification, effective communication, risk management, quality assurance, and more.

  5. A New Model Approach To Drug Shortage Prevention 3/15/2024

    The ISPE's Drug Shortages Prevention Model revamps its predecessor, the more prescriptive Drug Shortages Prevention Plan, with a focus on 12 key performance areas.

  6. Outsourcing Nirvana At Eli Lilly 3/4/2024

    Mark Butchko has been at Eli Lilly for 24 years, currently serving as Associate Vice President - Global Quality Laboratories. He draws from that longevity to describe what he’s currently experiencing, and what the future of outsourcing might look like from his vantage point.

  7. Risk And Supply Chain Continuity Management: Biologics Industry Perspectives 2/26/2024

    We spoke to three long-standing members of BioPhorum’s Risk and Business Continuity Workstream about their companies’ approaches to risk management, supply chain continuity, and what they learned from the pandemic. Among them are Melinda McCants, senior resiliency officer at Amgen.

  8. New DSCSA Guidance Details Layers Of Verification System Requirements 2/15/2024

    A recent FDA final guidance interpreting the DSCSA details verification systems expectations for trading partners. Just how they should meet these expectations, however, remains unclear.

  9. Creative Outsourcing Strategies, But Fill-Finish Still A Concern 2/5/2024

    Chief Editor Louis Garguilo wraps up his discussions with Thomas Rademacher, CEO, Emergex Vaccines, focusing on strategies that mix internal capacity, facility purchases, CDMOs, new technologies, and challenges with fill-finish outsourcing.

  10. Reinventing The Classic Pharma Campus 1/15/2024

    Perhaps your company is located on, or considering expanding to, a biopharma or life-sciences campus. Ever wonder how these “campuses” (or “parks”) materialize? Jason Benson of JLL Life Sciences Real Estate Solutions explains to chief editor Louis Garguilo.